This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07134335 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Enrollment | 180 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity &Amp; Overweight; Chronic Kidney Disease |
| Interventions | UBT251; UBT251; UBT251 |
| Start | Sep 1, 2025 |
| Primary completion | Jul 11, 2030 |
| Study completion | Jul 11, 2030 |
| Results posted | Not yet |
| Registry last updated | Nov 25, 2025 |
Compounds on this site that cite this trial
What the registry says the trial is about
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| log-transformed urinary albumin:creatinine ratiouff08UACRuff09 | 24 weeks |
8 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
- UBT251 Safety, Tolerability and Efficacy in Overweight or Obesity (Novo Nordisk Phase 2) (Phase 2 NCT07395687)
- UBT251 Injection Phase II Study (Overweight or Obesity) (Phase 2 NCT07177469)
- A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the (Phase 1 NCT07710729)
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood (Phase 1 NCT07710768)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
